Thank you for submitting your manuscript for consideration by The EMBO Journal. I have now received the report from the final referee and I enclose their comments below. As you will see they are in general positive about the role of PP4 in dephosphorylating Maf1, there are a number of issues that need to be clarified from Ref #1 and #3. Ref #2 raises several issues points 1, 3 and 4 seem to be reasonable and straight forward to be experimentally addressed (let me know if that is not the case), and points 5 and 6 can be addressed in the discussion. Given the support from the referees I would like to invite you to submit a revised version of the manuscript.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript. When you submit a revised version to the EMBO Journal, please make sure you upload a letter of response to the referees' comments. Please note that when preparing your letter of response to the referees' comments that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal ------------------------------------------------REFEREE COMMENTS Referee #1
The manuscript by Oler & Cairns identifies PP4 as the phosphatase primarily responsible for dephosphorylating Maf1 in budding yeast. This is an important discovery, because Maf1 is the key transcription factor that regulates pol III transcription in yeast, allowing adaptation to environmental conditions. Pol III is responsible for ~10% of nuclear transcription and produces essential products such as tRNA and 5S rRNA. By controlling its output, Maf1 has a profound effect on biosynthetic capacity and hence growth and proliferation. It represses pol III transcription when nutrients are scarce or cells are stressed in other ways, thereby conferring survival advantage. Oler & Cairns show that PP4 is instrumental in activating Maf1 under such stress conditions, through direct interaction. They also characterize which subunits of PP4 are required for this activity. These valuable discoveries are likely to have great impact. Maf1 has attracted considerable interest in recent years, because of its importance in pol III regulation. It is highly conserved through evolution and can suppress anchorage-independent colony formation by human cancer cells. Insights into Maf1 function should therefore be published as a matter of priority. I only have minor suggestions for revision. P3. TBP is described as "the initiation protein". I cannot see why it deserves that epithet any more than Brf1 or Bdp1.
P9. Overexpression of unfused Maf1 does not suppress growth. The authors might care to offer an explanation. Is it simply that the protein is phosphorylated and hence inactivated? If so, why does this not happen to the Rpc160-Maf1 fusion? Export?
In Fig 3A, the effect of pph3 deletion on Maf1 mobility seems more profound for rapamycin treatment than for nutrient deprivation, with the faster band predominating in the latter but not the former. Is this a consistent difference? How do the authors interpret it? Fig 6D. If I have understood correctly, there should not be Maf1 in lane 2, but it is clearly seen. Is this spill-over from lane 1. If so, this could be explained in the figure legend. I wondered whether the Pph3-TAP fraction would act promiscuously on any phosphoprotein in vitro. Has this been tested with a negative control? I don't think the overall conclusions would be undermined if specificity is low in vitro, but this information would help to inform interpretation of the experiment.
Referee #2
This manuscript investigates the potential role of PP4 phosphatase in the control of RNA polymerase III via the repressor protein Maf1. The regulation of RNA polymerase III is an area of importance and general interest appropriate for the EMBO Journal. Since research on yeast Maf1 is highly relevant to the regulation of RNA polymerase III in higher cells, this study will be seen as an important one to more than a specialized audience. Results by Oler and Cairns (1) show that PP4 phosphatase is required for acute Pol III repression, (2) identify Pph3 as the catalytic subunit involved in Maf1 dephosphorylation, (3) investigate the role of the PP4 core and regulatory/interacting proteins in Maf1 dephosphorylation, (4) show physical PP4 interaction with Maf1, (5) reconstitute PP4-dependent Maf1 dephosphorylation in vitro. The work follows up on a previous observation that questioned PP2A phosphatase involvement in Maf1 dephosphorylation. Oler and Cairns use Maf1-Rpc160 fusion as a tool for identifying relevant factors involved in phosphoregulation. Overall, I doubt if the design with Maf1-C160 fusion protein is suitable for answering the question posed. Although the authors make a strong claim to have identified PP4 as the nuclear Maf1 phosphatase that persuades Pol III repression, some standard experiments to verify such a claim are lacking.
Major critical remarks:
1 . Incorporation of Maf1-Rpc160 fusion to Pol III complex and its function in Pol III repression  should be directly documented in maf1-Δ strain. Interaction of HA-tagged fusion with Pol III  component (C82) should be shown by co-immunoprecipitation. Repression of Pol III transcription in  unfavorable growth conditions should be documented by the Northern blot using maf1-104 Rpc160  and maaf1-124 Rpc160 as negative controls. 2. Since the major point of the experimental design is that the dominant negative phenotype of Maf1-Rpc160 fusion serves as a tool for the identification of relevant factors involved in phosphorregulation of Maf1, this claim should be supported by stronger evidence. One piece of evidence is presented in Fig. 1E where fusions containing mutations in Maf1 show no negative effect. This data alone is fairly weak, raising the question whether other factors, not involved in Maf1 phosphorylation, also suppress the dominant negative effect of the Maf1-Rpc160 fusion protein. To learn this, the screen of yeast genomic library would be recommended.
3. Another piece of evidence presented is in vitro partial dephosphorylation ofMaf1 with a purified Pph3 catalytic subunit of PP4 phosphatase. Although general dephosphorylation is shown to occur in this assay, a negative control is missing. To give more weight to the in vitro assay, Maf1 should be incubated with immunoprecipitates of whole cell extracts containing (1) untagged Pph3 and (2) TP-tagged catalytically inactive Pph3. 4. The authors have shown no association of Pph3 with Pol III chromatin, but it would be more interesting to see if Pph3 inactivation (or PP4 inhibition) affects Maf1 association with Pol III chromatin under repressive conditions. 5. The presented model ( Fig. 7D) suggests that Msn5 plays a role in the bidirectional nuclear transport of Maf1, which is not true. It was shown previously that Msn5 facilitates the export of phosphorylated Maf1 out of the nucleus (Towpik et al, J. Biol. Chem 2008), but Maf1 importin was not identified. Moreover, although cytoplasmic Maf1 is mostly phosphorylated, it is unknown if Maf1 is imported to the nucleus in a phosphorylated form, as shown in Fig. 7D . Such a claim is justified neither by previous data nor by experiments presented by Oler and Cairns, thus the model should be modified. 2. The western blot of extract expressing Maf1-Rpc160-HA shows two bands when probed with α-HA. Why? Is the genomic Rpc160 HA-tagged ? This requires a comment.
3. Previous paper from Cairns laboratory (Roberts et al, 2006) reported that cells lacking Pck1 fail to cause Maf1 dephosphorylation in response to nutrient deprivation. What is the effect of pck1Δ on the dominant-negative phenotype of Maf1-Rpc160 fusion? 4. The authors observed the negative effects of pph1/2Δ and rrd2Δ on the Maf1-Rpc160 fusion. The reasons for this should be investigated or discussed.
5. Effect of pph3Δ on Maf1 localization should be described in "Discussion". The authors claim that "pph3Δ mutants show a defect/delay in the translocation /accumulation of Maf1 in the nucleus " (page 12, first paragraph). Moreover, the effect of pph3Δ on Maf1 localization was observed after 30 min but not after 6 h of nutrient deprivation. Since nuclear import of Maf1 is relatively fast, this observation suggests delay in Maf1 translocation to the pph3Δ nuclei. This interpretation is, however, not consistent with the presented model, according to which PP4-mediated dephosphorylation of Maf1 occurs in the nucleus. Alternatively, in a strain lacking Pph3, Maf1 would be exported to the cytoplasm more easily. Is this true? According to Towpik et al, 2008, Maf1 export out of the nucleus is relatively slow. Why no effect of prolonged nutrient deprivation on Maf1 localization in pph3Δ was observed? Noteworthy, Roberts et al, 2006 reported the seemingly contradictory results that Maf1 relocalization was more extensive after prolonged than acute repression. This requires a comment.
6. The authors have made an interesting observation that the CHX treatment results in Maf1 dephosphorylation but also effects Maf1 expression ( Fig. 7C) . The reasons for this should be discussed.
7.
In the Introduction the authors should cite a recent review of Orioli et al "RNA polymerase III transcription control elements: themes and variations" (Gene 2011).
Plasmid p2535 used for experiment presented in Fig. S3 is not listed in table S2
Referee #3
Oler and Cairns report on the regulation of the pol III repressor Maf1 in yeast. Maf1 is known to be regulated by phosphorylation, and a number of kinases have been reported to phosphorylate Maf1 in yeast cells. Here, the authors focus on dephosphorylation, and thus activation, of Maf1. They use an elegant tool, a fusion protein between Maf1 and the largest subunit of pol III, to separate effects on nuclear-cytoplasmic shuttling from effects on Maf1 phosphorylation and pol III repression. They show convincingly that previous results identifying PP2A as the main Maf1 phosphatase are erroneous, and that instead PP4 is the main phosphatase involve in acute Maf1 dephosphorylation. They also show that PP4 is nuclear, and mediates dephosphorylation in response to various stresses. I find the experiments convincing and the paper highly interesting.
As mentioned below in the specific comments, though, there are several indications that PP4 may not be the only Maf1 phosphatase (also it is clearly the main one). Perhaps the text should mention the possibility of additional minor Maf1 phosphatases.
Specific comments :
-end of 3rd paragraph of the introduction : it would be useful for the reader to indicate that the evidence that movement to the nucleus is insufficient to repress pol III transcription is based on studies in msn5-Δ cells.
-4th paragraph of the introduction : specify yeast Maf1. Figure S1, lane 2 : what are the two bands ? Both are absent in lane 1, suggesting they are both derived from the Maf1-RPC160 construct. It seems important to sort this out. p. 10, 2nd paragraph : please introduce Psy4-in the text. Note that for the reader not versed in PP2A and PP4 subunits, the text describing Figures 2, S3 and S4 is difficult to follow. It would be so much simpler to have a table with two columns listing the PP2A and PP4 subunits. The information provided now on p. 15, 1st paragraph, describing components of PP4, should be incorporated in this table and mentioned in the text at this point. Figure 2A : Psy4 seems to rescue growth sligthly when comparing to WT cells. Text should be adapted. Figure 3A : it woul be nice to reproduce these data without the complication of the CHX treatment. One would imagine that newly translated Maf1 will be a minor component under nutrient deprivation or rapamycin addition during the short period of 25 min. In any case, the experiment as it stands suggests that with nutrient deprivation, another phosphatase (independent of Pph3) is capable of dephosphorylating Maf1, as there is some dephosphorylation in lane 2 in the pph3Δ panel. Figure 4A : there is some dephosphorylation in the psy2 deletion mutant. We thank all three reviewers for their insightful comments -which we addressed to the best of our ability -and which have improved the paper significantly. We provide an extensive point-by-point response. Although the changes were fairly extensive, I'll note here the major additions to the work: 1) We performed Northern analysis on the two maf1 hypomorphic alleles depicted in Figure 1E , and showed (as predicted) restoration of growth ability is accompanied by a restoration of tRNA transcription. This new data is presented in Figure 1F . 2) In a major addition to the paper, we performed ChIP on Maf1 and show markedly lower levels of association with Pol III genes in a pph3 mutant, and a serious defect in Maf1 recruitment to Pol III loci during nutrient stress in the pph3 mutant. This new data is presented in Figure 3F . 3) We examined the behavior of a phosphorylation defective allele (maf1-7A), and found that this allele is particularly effective in repressing Pol III in the fusion format, and that its ability to confer repression is partially suppressed in a pph3 mutant. This new data is presented in new Supplemental Figure S8 . 4) We examined the effect of overexpression of Maf1 itself (with a GAL promoter) and observe moderate reductions in Pol III transcription, but no growth defect, consistent with a threshold for growth impact that requires considerable Pol III repression (>50%). This data is provided in new Supplemental Figure S2 .
Comments from Reviewer #1
We thank this reviewer for their appreciation of the work, and for the helpful comments, which have improved the paper.
P3. TBP is described as "the initiation protein". I cannot see why it deserves that epithet any more than Brf1 or Bdp1.
We agree, and were simply being brief. We have changed the text to reflect that TFIIIB is the initiation complex.
Although overexpressed Maf1 does not suppress growth, overexpression does partially repress Pol III, to ~50% of WT levels, but apparently not at a sufficient level to cause a growth defect. Thus, the protein is likely partially unphosphorylated, and conferring moderate repression. This is consistent with a certain threshold (>50%) that must be crossed to observe a growth defect, with tRNA abundance rate limiting below that level. However, in the fusion context repression is considerably greater and a growth defect is clearly observed. We have commented on this issue in the discussion.
In Fig 3A, the effect of pph3 deletion on Maf1 mobility seems more profound for rapamycin treatment than for nutrient deprivation, with the faster band predominating in the latter but not the former. Is this a consistent difference? How do the authors interpret it?
The reviewer has a keen eye; a consistent difference between rapamycin treatment and nutrient deprivation is lower levels of Maf1 following rapamycin treatment, but not in nutrient deprivation. We don't know the reason for this curiosity, though we intend to follow up in future work. We note that this is only observed when we pre-treat the cells with cycloheximide (CHX) -needed to ensure that we are looking at the state of existing Maf1. If one adds rapamycin (Rap) to cells that are not treated with CHX, then a robust band is seen of dephosphorylated Rather than spill-over of Maf1, other blots indicated to us that this was cross-reactivity of Pph3-TAP, which is at the same size as dephosphorylated Maf1. This was actually addressed in the Methods section of the manuscript, but we will move this to the legend. According to your suggestion and that of another reviewer, we repeated the phosphatase assay, making an effort to get rid of this cross-reactivity, especially since it is at the same size as Maf1. Although progress was made at removing this cross-reactivity, we encountered a different problem with the new preps. Unfortunately, we picked up a low level protease in the preps that partially degraded the substrate in longer incubations, thus making it impossible for us to extend our work on the in vitro experiments in the time frame of revision.
Comments from Reviewer #2
We thank the reviewer for their detailed comments and suggestions (especially the important Maf1 ChIP experiment) most of which we were able to address, and used to enhance the paper.
Major critical remarks: The reviewer requests further characterization of the Maf1-Rpc160 fusion construct. We agree that a stringent control involves verifying via Co-IP that our Maf1-Rpc160 fusion integrates into Pol III, and not simply a rogue subunit. First, we note that we have shown in the paper the complementation of the Rpc160 null by the fusion, so assembly is essentially assured. Furthermore, we have done the biochemical test as the reviewer requested, with one slight change. All of our experiments with our Maf1-Rpc160 fusion (the fusion growth defect) were conducted in a MAF1+ strain, not a maf1D strain, so it seemed proper to us to assay incorporation in a MAF1+ strain. Also, the genomic Maf1 status should have no bearing on the ability of the fusion to assemble into RNA Pol III. Therefore, we did the experiment requested, but in the WT MAF1+ strain. Our results demonstrate that the Maf1-Rpc160 fusion incorporates into the Pol III complex, as shown by co-immunoprecipitation (co-IP) with Rpc82-myc, both by IP of Rpc82-myc and by IP of the fusion. To address the second request, we performed Northern blot using maf1-104-Rpc160 and maf1-124-Rpc160 as in Figure  1B , with induction of the mutant fusion constructs (or Rpc160, Maf1-Rpc160) with galactose. Consistent with the rescue that we see in the plate fusion growth assay for the mutant fusion constructs, we also see attenuated repression of Pol III transcription in the mutant fusion constructs compared to the fusion with WT Maf1. These data have been added to the Results section, including a new figure panel, Fig. 1F .
2.
Since the major point of the experimental design is that the dominant negative phenotype of Maf1-Rpc160 fusion serves as a tool for the identification of relevant factors involved in phosphor-regulation of Maf1, this claim should be supported by stronger evidence. One piece of evidence is presented in Fig. 1E where fusions containing mutations in Maf1 show no negative effect. This data alone is fairly weak, raising the question whether other factors, not involved in Maf1 phosphorylation, also suppress the dominant negative effect of the Maf1-Rpc160 fusion protein. To learn this, the screen of yeast genomic library would be recommended.
While screening a genomic library is a worthwhile experiment in the long term, and could produce new factors, this is labor intensive and would take a considerable amount of time. Notably, in this paper we already used the fusion to identify three new factors needed for Maf1 dephosphorylation, Psy2, Rrd1 and Tip41, as well as determining the members of PP4 that are not needed. Therefore, we feel that the tool has already proven its usefulness in principle and practice, and that screens represent an additional use in future work.
3.
Another piece of evidence presented is in vitro partial dephosphorylation of Maf1 with a purified Pph3 catalytic subunit of PP4 phosphatase. Although general dephosphorylation is shown to occur in this assay, a negative control is missing. To give more weight to the in vitro assay, Maf1 should be incubated with immunoprecipitates of whole cell extracts containing (1) untagged Pph3 and (2) TP-tagged catalytically inactive Pph3.
The reviewer has requested additional controls for the in vitro phosphatase experiment. To address this, we performed the phosphatase assay with IgG immunoprecipitates from the following strains: 1) Pph3-TAP 2) Psy2-TAP pph3D [PPH3] 3) Psy2-TAP pph3D [empty] and 4) Psy2-TAP pph3D [pph3-H112N]. pph3-H112N is a catalytic dead form of Pph3. The first two strains showed activity on Rad53 while the other two strains showed no activity on Rad53, as expected. Unfortunately, there were some complications in the experiment due to a low-level protease acting on Maf1 in some of our preparations, as discussed in the response to the first reviewer, preventing us from further developing this experiment in the time frame of revision.
The authors have shown no association of Pph3 with Pol III chromatin, but it would be more interesting to see if Pph3 inactivation (or PP4 inhibition) affects Maf1 association with Pol III chromatin under repressive conditions.
This was an excellent suggestion, and important for testing the model, and high on our list of priorities for extending our work. We performed Maf1 ChIP in WT and pph3D cells and found that basal Maf1 ChIP levels are lower in pph3D cells compared to WT, and recruitment of Maf1 upon nutrient deprivation is at a much lower level in pph3D than in WT cells. This is consistent with our model for PP4 in maintaining a basal level of dephosphorylated Maf1, as well as dephosphorylation of Maf1 in response to stress. We have added these results to the main Results section and have added a new figure panel, Figure 3F . We believe this is a major addition to the manuscript.
5.
The presented model (Fig. 7D) suggests that Msn5 plays a role in the bidirectional nuclear transport of Maf1, which is not true. It was shown previously that Msn5 facilitates the export of phosphorylated Maf1 out of the nucleus (Towpik et al, J. Biol. Chem 2008) , but Maf1 importin was not identified. Moreover, although cytoplasmic Maf1 is mostly phosphorylated, it is unknown if Maf1 is imported to the nucleus in a phosphorylated form, as shown in Fig. 7D . Such a claim is justified neither by previous data nor by experiments presented by Oler and Cairns, thus the model should be modified.
The reviewer is noting something that we did not intend to imply. The model is intended to indicate that Msn5 is only involved in the export, i.e., the left side of the double-arrow. To clarify, we have added a question mark on the import side of the double arrow in the model figure.
In regard to the second comment, it has not been determined whether Maf1 is imported in a phosphorylated or dephosphorylated state. One might think that dephosphorylation would occur in the cytoplasm before translocation to the nucleus. Indeed, previous data from others suggested that phosphorylation of serines near the NtNLS is somewhat inhibitory to nuclear accumulation (Moir et al., 2006) , suggesting that dephosphorylation of these residues is required for optimal translocation to the nucleus. However, even without a functional NtNLS, Maf1 retains an intact CtNLS that appears to be unaffected by phosphorylation, and some level of Maf1 could likely translocate to the nucleus even in a phosphorylated state. This allows a model in which Maf1 is imported to the nucleus regardless of phosphorylation status, with phosphorylation enabling its continual export by Msn5, producing a mostly cytoplasmic localization under normal growth conditions. Consistent with this, and as shown in Towpik et al (2008) , in the absence of Msn5, phosphorylated Maf1 accumulates in the nucleus. Whether this Maf1 was phosphorylated after arriving in the nucleus or before is not known, but dephosphorylation is still able to occur, suggesting that the phosphatase is present in the nucleus. This is consistent with our results showing that Psy2-GFP is localized to the nucleus. Thus, dephosphorylation has the effect of preventing export of phosphorylated Maf1, leading to the apparent nuclear localization. We have extended the discussion to clarify this point.
6.
It is not clear to me how the data in this manuscript fits with Oficjalska-Pham et al. (Molecular Cell 2006) supporting a generally anticipated model that PP2A dephosphorylates Maf1 in the cytoplasm prior to its import to the nucleus. Do the authors claim that data presented in Oficjalska-Pham et al is wrong? Other findings presented by Zagaroza et al (Mol Cell Biol 1998) are consistent with Oficjalska-Pham et al, strongly indicating the role of PP2A in Pol III control. Possibly Maf1 is dephosphorylated by PP2A in the cytoplasm and by PP4 in the nucleus. The authors should discuss this possibility and modify their model (Fig. 7D) .
Corrections and clarifications of the work of colleagues should be done carefully and professionally, so we have provided a concise and collegial way in our paper, but it appears that our attempt in the initial submission may not have been sufficient. The Oficjalska-Pham paper is an excellent paper in many respects, and we agree with virtually all of the data they presented. However, we are questioning certain assumptions and interpretations. Our data (and recent data of others) shows that Pph3 is not a member of PP2A, but rather PP4. They assumed incorrectly that Pph3 is a member of PP2A, due to some confounding genetics by others in the prior literature. In our view, this likely affected the design of experiments and their interpretation, which led to an incorrect main conclusion in their paper -that PP2A is the major Maf1 phosphatase. If we look at Figure 6 in their paper, the clearest defect in Maf1 dephosphorylation is observed in pph3D pph21D cells compared to WT, with minimal additive effects seen in the triple mutant pph3D pph21D pph22-ts (e.g., nuclear localization, Maf1 dephosphorylation). Since it is well established that Pph21 and Pph22 are functionally redundant, the pph3D pph21D strain is essentially only a pph3D mutant, with functional PP2A provided by Pph22. Thus, in retrospect, one can imply that dephosphorylation relies on PP4 and not PP2A, which is counter to a main conclusion of their paper. To prove that it is indeed PP4 requires the work done in our manuscript.
In addition, the historical evidence suggesting that PP2A could be the phosphatase is based on Tpd3 acting as a scaffold and repressor of PP2A catalytic subunits. Specifically, tpd3 was identified as a mutant that caused inhibition of tRNA transcription (van Zyl et al., Genetics 1989; van Zyl et al., Mol Cell Biol, 1992) . The study discussed the possibility that mutated tpd3 could release PP2A catalytic subunits as rogue phosphatases, dephosphorylating an unidentified repressor. Whether this is the case or not is unknown, but it is well established (including studies of the crystal structure of the heterotrimeric complex) that the function of Tpd3/PP2A A is to act as a scaffold to bring together a PP2A catalytic subunit with a regulatory subunit for their proper function (e.g., Jiang, Microbiol Mol Biol Rev, 2006; Cho & Xu, Nature, 2007) . Indeed, tpd3D mutants phenocopy pph21D pph22D double mutants in many ways (Wang and Ng, Mol Biol Cell, 2006 ; current study), suggesting that tpd3D mutants simply lack proper PP2A function, rather than having overactive rogue phosphatase activity towards natural substrates. Furthermore, even if Pph21/22 is active on Maf1 in tpd3D mutant cells, this does not imply that Maf1 is a natural substrate of PP2A in normal conditions. Most importantly, in the experiments we have performed with PP2A mutants, we see no visible role for dephosphorylation of Maf1 -i.e., in either pph21D pph22D or tpd3D mutants, we see Maf1 can be fully dephosphorylated in nutrient deprivation and rapamycin treatment. Anecdotally, we see that Maf1 is dephosphorylated much quicker in these mutants in S288C, and in W303 background, Maf1 is largely dephosphorylated in these mutants even without stress (Roberts et al, 2006) . If PP2A plays a role in Maf1 regulation, these results suggest that it plays a role in maintaining Maf1 phosphorylation, rather than dephosphorylation of Maf1. Consistent with this, we find that in PP2A mutants, the fusion growth defect is intensified, suggesting that Maf1 is less phosphorylated and therefore repressing Pol III to a greater extent. Only in mutants of PP4 or related cofactors do we see reduced Maf1 dephosphorylation. Thus, PP2A mutations likely cause stress, which likely causes a partial dephosphorylation of Maf1 via PP4. Finally, our read of the Zaragoza et al paper does not provide evidence for PP2A dephosphorylating Maf1. If anything, the role of PP2A in Pol III control may help maintain Maf1 phosphorylation.
Minor critical remarks 1. Fig. 1 should be improved and additional comments in the Result section are desirable. a.
There is less RNA loaded in lanes 1-4 than in lanes 5-8 in Fig. 1B (since there is no reason for the increase of U4 transcription in the galactose medium). This unequal loading suggests that overexpression of Rpc160 alone has a negative effect on tRNA transcription.
Yes, if one examines the ratios, overexpression of Rpc160 does reduce tRNA expression moderately. However, fusion to Maf1 dramatically increases repression and also confers a growth defect, which are the important results and comparison. Furthermore, we follow up with experiments that show the relevance of the Maf1 function and phosphorylation for this affect. However, we will note in the results section that the observed ratios do support a moderate/modest reduction in tRNA expression simply with overexpression of Rpc160.
b.
The growth phenotype of rpc160-Δ[PGALMaf1-Rpc160] should be documented more convincingly to show the dominant negative effect of Maf1-Rpc160 fusion. Are the FOA(+) colonies really unable to grow on the Sc-ura medium? Why do rpc160-Δ[PGAL-Rpc160] grow better on the galactose+FOA medium than wt ? Are the growth defects of rpc160-&#x0394;[PGALMaf1-Rpc160] and wt[PGALMaf1-Rpc160] the same?
To address the first question, we repeated the experiment in Fig. 1D and restreaked the FOA+ rpc160D strains onto various plates, including -URA to ensure that no WT P(MET25)Rpc160::URA plasmid remains. As expected, 6/6 colonies restruck would not grow on -URA, suggesting that they are lacking any WT Rpc160.
For the second comment, we don't believe that rpc160D [PGALRpc160] grows better than WT [PGALRpc160] on galactose+FOA; the number of colonies may be slightly higher as 'frog spotting' is never strictly quantitative, but the colony size is the same. For the third comment: in general, the growth defect is not characterized by fewer colonies coming up than in the strains not harboring the fusion, but smaller colonies. In this case, the colony size in WT [PGALMaf1-Rpc160] and rpc160D [PGALMaf1-Rpc160] is the same size, therefore we believe that the growth defect is the same.
c.
The same construct/strain is designated differently in Fig1B (M-Rpc160), Fig. 1C ,E (Maf1-Rpc160). 1D wt(PGALMaf1-Rpc160) and S1 (Maf1-Rpc160-HA)? Am I wrong?
Yes, these all refer to the same construct. We have corrected the manuscript so that all references are in the format "Maf1-Rpc160".
2.
The western blot of extract expressing Maf1-Rpc160-HA shows two bands when probed with α-HA. Why? Is the genomic Rpc160 HA-tagged? This requires a comment.
The lower band is evidently a degradation product, likely caused by the presence of the flexible linker; when we omit protease inhibitors, or when we incubate the extract even for short periods of time the lower band increases (and other shorter bands become evident). We have added a note in the figure legend to denote this.
3.
Previous paper from Cairns laboratory (Roberts et al, 2006) reported that cells lacking Pck1 fail to cause Maf1 dephosphorylation in response to nutrient deprivation. What is the effect of pck1Δ on the dominant-negative phenotype of Maf1-Rpc160 fusion?
Working with and interpreting a pkc1Δ strain is a real challenge as it is a lethal mutation unless one grows on special medium to balance osmotic problems, and even in those conditions it grows poorly. This is why it was a minor supplemental point in that previous paper, and was not addressed in our current work. Nevertheless, to address this comment we tested the Maf1-Rpc160 fusion growth assay with pkc1Δ cells and found that the strain was sicker when harboring the fusion contruct. In fact, even with Rpc160 alone, the cells were very sick compared to empty vector. We had to modify the assay slightly to plate the cells to plates containing 1M sorbitol, to enable pkc1Δ viability. This causes a slight reduction in the ability to resolve rescue (see WT versus pph3Δ mutant). According to our previous data, pkc1Δ cells are deficient in dephosphorylation due to nutrient deprivation but not rapamycin. The ability to observe dephosphorylation in one condition but not another would be interesting to follow up in the future, but is not in the scope of this paper, which focuses on identifying the main Maf1 phosphatase for general Maf1-dependednt Pol III repression. Thus, we would rather leave this minor point out of the current paper, as it is a tangent not related to our conclusions.
4.
The authors observed the negative effects of pph1/2Δ and rrd2Δ on the Maf1-Rpc160 fusion. The reasons for this should be investigated or discussed.
Our goal was to identify the main Maf1 phosphatase. The lack of major involvement of PP2A in dephosphorylation is a major point, whereas its possible slight 'negative' role is a minor point, simply serving to reinforce the fact that, if anything, PP2A works the opposite way to what was previously reported. To meet the reviewer's request, we have slightly expanded the Discussion to make this point clearer -and to state the obvious possibility that PP2A mutations may cause stress that is mediated through PP4 -but we simply do not know the details, nor are we planning to pursue this.
5.
Effect of pph3Δ on Maf1 localization should be described in "Discussion". The authors claim that "pph3Δ mutants show a defect/delay in the translocation /accumulation of Maf1 in the nucleus " (page 12, first paragraph). Moreover, the effect of pph3Δ on Maf1 localization was observed after 30 min but not after 6 h of nutrient deprivation. Since nuclear import of Maf1 is relatively fast, this observation suggests delay in Maf1 translocation to the pph3Δ nuclei. This interpretation is, however, not consistent with the presented model, according to which PP4-mediated dephosphorylation of Maf1 occurs in the nucleus. Alternatively, in a strain lacking Pph3, Maf1 would be exported to the cytoplasm more easily. Is this true? According to Towpik et al, 2008 , Maf1 export out of the nucleus is relatively slow. Why no effect of prolonged nutrient deprivation on Maf1 localization in pph3Δ was observed? Noteworthy, Roberts et al, 2006 reported the seemingly contradictory results that Maf1 relocalization was more extensive after prolonged than acute repression. This requires a comment. This is an interesting point that requires additional context. Our Maf1 kinetics and yields in the nucleus are consistent with that seen by other groups. During acute repression, enough Maf1 enters and remains in the nucleus to confer acute repression. Second, as time goes on, the new Maf1 that is synthesized is unphosphorylated, and therefore competent to repress, and should stay nuclear. Therefore, acute repression requires the dephosphorylation of a portion of Maf1 (relying on Pph3/PP4), and long-term repression likely utilizes recently synthesized Maf1, which is unphosphorylated and nuclear and independent of Pph3/PP4. The most likely reason for accumulation of Maf1 to the nucleus in the extended timepoint in pph3Δ is due to a large amount of recently-translated, unphosphorylated Maf1, as stated in the manuscript.
6.
The authors have made an interesting observation that the CHX treatment results in Maf1 dephosphorylation but also effects Maf1 expression (Fig. 7C) . The reasons for this should be discussed.
If the effect on Maf1 expression the reviewer is referring to is the reduced protein seen on western blot in CHX-treated cells compared to T=0, then we will clarify that as CHX is known to block translation, a lower level is expected, as new protein will not replace degraded protein. This technique allows one to see the fate of existing Maf1 (phosphorylation status) and its rate of degradation.
7.
In the Introduction the authors should cite a recent review of Orioli et al "RNA polymerase III transcription control elements: themes and variations" (Gene 2011) . This citation has been added.
8.
Plasmid p2535 used for experiment presented in Fig. S3 is
not listed in table S2
This has been corrected to say p2353 in the figure legend.
From Reviewer #3:
We thank this reviewer for the many positive comments and suggestions. We thank this reviewer for their positive perspective -we entirely agree! As mentioned below in the specific comments, though, there are several indications that PP4 may not be the only Maf1 phosphatase (also it is clearly the main one). Perhaps the text should mention the possibility of additional minor Maf1 phosphatases.
We agree, and have added this to the paper.
Specific comments :
Agreed, we have added mention of msn5D to the paper.
-4th paragraph of the introduction : specify yeast Maf1.
Agreed, we have specified yeast Maf1. Figure S1, lane 2 : what are the two bands ? Both are absent in lane 1, suggesting they are both derived from the Maf1-RPC160 construct. It seems important to sort this out.
As discussed in the response to reviewer 2, it appears that it is a degradation product. Importantly, although these smaller degradation products exist, it is the full-length version of Maf1-Rpc160 that incorporates into the Pol III complex. We have introduced Psy4 at the spot mentioned and added a table to the text for clarification. Figure 2A : Psy4 seems to rescue growth sligthly when comparing to WT cells. Text should be adapted.
The effect is rather subtle, but we agree that there is a slight amount of rescue. We have adapted the text accordingly. Figure 3A : it woul be nice to reproduce these data without the complication of the CHX treatment. One would imagine that newly translated Maf1 will be a minor component under nutrient deprivation or rapamycin addition during the short period of 25 min. In any case, the experiment as it stands suggests that with nutrient deprivation, another phosphatase (independent of Pph3) is capable of dephosphorylating Maf1, as there is some dephosphorylation in lane 2 in the pph3Δ panel.
As the reviewer has suggested, we repeated the experiment for Fig. 3A and it appears that newly translated Maf1 may not be a major component at this short time point. This has been added to the Results section and the Supplementary Data. Figure 4A : there is some dephosphorylation in the psy2 deletion mutant.
2nd Editorial Decision 16 December 2011
Thank you for submitting a revised version of the your manuscript, I have discussed the decision with one of the original referees and we find that you have satisfactorily addressed all the initial concerns raised. I am happy to accept the manuscript for publication in The EMBO Journal. You will receive the official letter in the next day or so.
Editor
The EMBO Journal ------------------------------------------------REFEREE COMMENTS I am happy with the responses given by Oler & Cairns to my concerns. I also think that they have done a good job of addressing the issues raised by referee 2.
It is an important story of good quality. I recommend publication.
